Penpulimab in combination with lenalidomide and R-GemOx regimen (R2-GemOx-PD1i) in relapsed or refractory diffuse large B-cell lymphoma: a multicenter, single-arm, phase 2 trial.

BMC Med · 2026 · PMC12983746 · PMID 41656201

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Exploratory outcomes, assessed by univariate analyses, suggested that only elevated LDH levels showed a trend towards worse PFS (HR: 2.0; 95% CI 0.92‒4.3; P value: 0.08), while high LDH levels (HR: 4.1; 95% CI 1.3‒13.2; P value: 0.02) and the number of extra nodal sites more than 1 (HR: 4.0; 95% CI 1.4‒11.6; P value: 0.01) were significantly associated with worse OS (Additional File 1: Table S1).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.